MetaCap

AbCellera Biologics (ABCL) vs Arcutis Biotherapeutics (ARQT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 176.1% versus a loss of 10.6%. Over five years, ARQT leads with a +58.1% price change compared with -30.7% for ABCL. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.16 billion), about 1.1 times the size, while AbCellera Biologics is growing revenue faster (+160.6% vs +91.3%).

Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -194.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%ARQT-10.61%
+340%+144%-52%
Nov 21, 20251 yearNov 20, 2026
ABCL-38.67%ARQT+44.91%
+85%-7%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus ARQT key metrics
MetricABCLARQT
Share price$9.69$26.36
Market cap$3.16B$3.33B
1-day change-7.45%-2.98%
YTD return+183.33%-9.23%
1-year return+176.07%-10.61%
5-year return-30.74%+58.13%
P/E ratio (TTM)—119.82
Forward P/E—24.09
EPS (TTM)$-0.48$0.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M$376.07M
Revenue growth (YoY)+160.56%+91.34%
Net income (latest FY)$-146.41M$-16.14M
Gross margin—90.24%
Operating margin-288.98%-3.25%
Net margin-194.88%-4.29%
52-week high$15.02$34.80
52-week low$2.75$19.30
Distance from 52-week high-35.46%-24.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+92.67%+53.19%
Average volume4.34M2.58M
Shares outstanding326.62M126.46M
Employees562354
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed ARQT by 186.7 percentage points over the past year.
  • Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
  • AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +91.34%).

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About Arcutis Biotherapeutics

ARQT stock →

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees

ABCL vs ARQT FAQ

Which is bigger, AbCellera Biologics or Arcutis Biotherapeutics?

Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.16B for AbCellera Biologics (ABCL).

Which stock has performed better over the past year, ABCL or ARQT?

ABCL returned +176.07% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and Arcutis Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons